In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3115-3124

  Pereira, Marcus R ^a   Henrich, Philipp P ^a   Sidhu, Amar Bir Singh ^a,b   Johnson, David ^b,f   Hardink, Joel ^c   Van Deusen, Jeffrey ^c   Lin, Jian ^c   Gore, Katrina ^d   O'Brien, Connor ^a   Wele, Mamadou ^e   Djimde, Abdoulaye ^e   Chandra, Richa ^c   Fidock, David A ^a,b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e UNIVERSITY OF BAMAKO   (Mali)

^f HEALTH AND SAFETY EXECUTIVE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZITHROMYCIN; CHLOROQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL;

AMLODIPINE; ANIMALS; ANTIMALARIALS; AZITHROMYCIN; CHLOROQUINE; DRUG INTERACTIONS; FEMALE; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 79959227019     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01566-10     Document Type: Article

References (95)

1. Andersen, S. L., et al. 1995. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am. J. Trop. Med. Hyg. 52:159-161.
2. Anderson, S. L., et al. 1995. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann. Intern. Med. 123:771-773.
3. Anderson, T. J., X. Z. Su, M. Bockarie, M. Lagog, and K. P. Day. 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119:113-125.
4. Basco, L. K., and J. Le Bras. 1991. Plasmodium falciparum: in vitro drug interaction between chloroquine and enantiomers of amlodipine. Exp. Parasitol. 72:262-270.
5. Bell, A. 2005. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol. Lett. 253:171-184.
6. Ben Mamoun, C., S. T. Prigge, and H. Vial. 2010. Targeting the lipid metabolic pathways for the treatment of malaria. Drug Dev. Res. 71:44-55.
7. Biswas, S. 2001. In vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum. J. Postgrad. Med. 47:240-243.
8. Bitonti, A. J., and P. P. McCann. 1989. Desipramine and cyproheptadine for reversal of chloroquine resistance in Plasmodium falciparum. Lancet ii:1282-1283.
9. Boulanger, D., et al. 2010. Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children. Malar. J. 9:363.
10. Bray, P. G., M. Mungthin, R. G. Ridley, and S. A. Ward. 1998. Access to hematin: the basis of chloroquine resistance. Mol. Pharmacol. 54:170-179.
11. Bronzan, R. N., et al. 2007. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J. Infect. Dis. 195:895-904.
12. Burgess, S. J., et al. 2010. Synthesis, structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds. J. Med. Chem. 53:6477-6489.
13. Chico, R. M., R. Pittrof, B. Greenwood, and D. Chandramohan. 2008. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar. J. 7:255.
14. Curran, M. P. 2010. Amlodipine/atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs 70:191-213.
15. Dahl, E. L., and P. J. Rosenthal. 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51:3485-3490.
16. Davis, T. M., T. Y. Hung, I. K. Sim, H. A. Karunajeewa, and K. F. Ilett. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87.
17. Deloron, P., et al. 1991. In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine. Antimicrob. Agents Chemother. 35:1338-1342.
18. Dondorp, A. M., et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
19. Dunne, M. W., et al. 2005. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J. Infect. Dis. 191:1582-1588.
20. Dunne, M. W., et al. 2005. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India. Am. J. Trop. Med. Hyg. 73:1108-1111.
21. Eastman, R. T., and D. A. Fidock. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7:864-874.
22. Egan, T. J., and C. H. Kaschula. 2007. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect. Dis. 20:598-604.
23. Ekland, E. H., and D. A. Fidock. 2008. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38:743-747.
24. English, M., J. Punt, I. Mwangi, K. McHugh, and K. Marsh. 1996. Clinical overlap between malaria and severe pneumonia in African children in hospital. Trans. R. Soc. Trop. Med. Hyg. 90:658-662.
25. Faulkner, J. K., D. McGibney, L. F. Chasseaud, J. L. Perry, and I. W. Taylor. 1986. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22:21-25.
26. Fidock, D. A., T. Nomura, and T. E. Wellems. 1998. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol. Pharmacol. 54:1140-1147.
27. Fidock, D. A., P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3:509-520.
28. Friesen, J., et al. 2010. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci. Transl. Med. 2:40ra49.
29. Gibbons, J., J. Pugh, G. Dimopoulos-Italiano, and R. Pike. 2006. A qualitative study of amlodipine and its related compounds by electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20:1715-1723.
30. Gingras, B. A., and J. B. Jensen. 1992. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 47:378-382.
31. Gingras, B. A., and J. B. Jensen. 1993. Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei. Am. J. Trop. Med. Hyg. 49:101-105.
32. Girard, A. E., et al. 1987. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 31:1948-1954.
33. Goodman, C. D., V. Su, and G. I. McFadden. 2007. The effects of antibacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152:181-191.
34. Gray, R. H., et al. 2001. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am. J. Obstet. Gynecol. 185:1209-1217.
35. Haug, S., et al. 2010. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin. Infect. Dis. 51:571-574.
36. Hawking, F. 1966. Chloroquine resistance in Plasmodium berghei. Am. J. Trop. Med. Hyg. 15:287-293.
37. Juliano, J. J., J. J. Kwiek, K. Cappell, V. Mwapasa, and S. R. Meshnick. 2007. Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg. Infect. Dis. 13:872-877.
38. Kalilani, L., et al. 2007. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One 2:e1166.
39. Kallander, K., et al. 2008. Delayed care seeking for fatal pneumonia in children aged under five years in Uganda: a case-series study. Bull. World Health Organ. 86:332-338.
40. Kallander, K., J. Nsungwa-Sabiiti, and S. Peterson. 2004. Symptom overlap for malaria and pneumonia-policy implications for home management strategies. Acta Trop. 90:211-214. (Pubitemid 38283771)
41. Kelly, J. X., et al. 2009. Discovery of dual function acridones as a new antimalarial chemotype. Nature 459:270-273.
42. Konate, L., et al. 1999. Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans. R. Soc. Trop. Med. Hyg. 93(Suppl. 1):21-28.
43. Krogstad, D. J., et al. 1987. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238:1283-1285.
44. Krogstad, D. J., and P. H. Schlesinger. 1987. The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am. J. Trop. Med. Hyg. 36:213-220.
45. Kuhn, Y., P. Rohrbach, and M. Lanzer. 2007. Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell. Microbiol. 9:1004-1013.
46. Kuschner, R. A., et al. 1994. Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum. Lancet 343:1396-1397. (Pubitemid 24167514)
47. Kyle, D. E., W. K. Milhous, and R. N. Rossan. 1993. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. Am. J. Trop. Med. Hyg. 48:126-133.
48. Lakshmanan, V., et al. 2005. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24:2294-2305. (Pubitemid 41032582)
49. Laufen, H., and M. Leitold. 1994. Enantioselective disposition of oral amlodipine in healthy volunteers. Chirality 6:531-536. (Pubitemid 24333334)
50. Laufer, M. K., et al. 2006. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355:1959-1966.
51. Martin, S. K., A. M. Oduola, and W. K. Milhous. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901.
52. Mehlotra, R. K., et al. 2001. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc. Natl. Acad. Sci. U. S. A. 98:12689-12694.
53. Mwai, L., et al. 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malar. J. 8:106.
54. Nakornchai, S., and P. Konthiang. 2006. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 100:185-191. (Pubitemid 46176762)
55. Nakornchai, S., and P. Konthiang. 2006. Potentiation of antimalarial drug action by chlorpheniramine against multidrug-resistant Plasmodium falciparum in vitro. Parasitol. Int. 55:195-199.
56. Noedl, H. 2009. ABC-antibiotics-based combinations for the treatment of severe malaria? Trends Parasitol. 25:540-544.
57. Noedl, H., et al. 2006. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin. Infect. Dis. 43:1264-1271.
58. Noedl, H., et al. 2007. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob. Agents Chemother. 51:651-656.
59. Noedl, H., et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
60. Noedl, H., D. Socheat, and W. Satimai. 2009. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361:540-541.
61. O'Dempsey, T. J., et al. 1993. Overlap in the clinical features of pneumonia and malaria in African children. Trans. R. Soc. Trop. Med. Hyg. 87:662-665.
62. Oduola, A. M., et al. 1993. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. Trans. R. Soc. Trop. Med. Hyg. 87:81-83.
63. Ohrt, C., G. D. Willingmyre, P. Lee, C. Knirsch, and W. Milhous. 2002. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46:2518-2524.
64. O'Neill, P. M., et al. 2006. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr. Top. Med. Chem. 6:479-507.
65. Pachot, J. I., R. P. Botham, K. D. Haegele, and K. Hwang. 2003. Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6:1-12.
66. Pagola, S., P. W. Stephens, D. S. Bohle, A. D. Kosar, and S. K. Madsen. 2000. The structure of malaria pigment beta-haematin. Nature 404:307-310.
67. Park, J. Y., et al. 2006. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin. Ther. 28:1837-1847.
68. Peters, W. 1987. Chemotherapy and drug resistance in malaria, 2nd ed. Academic Press, London, United Kingdom.
69. Peters, W., R. Ekong, B. L. Robinson, D. C. Warhurst, and X. Q. Pan. 1989. Antihistaminic drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet ii:334-335.
70. Peters, W. 1987. Chemotherapy and drug resistance in malaria, 2nd ed. Academic Press, Inc., London, United Kingdom.
71. Peuchant, O., et al. 2009. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J. Antimicrob. Chemother. 64:52-58.
72. Poehlsgaard, J., and S. Douthwaite. 2005. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 3:870-881.
73. Puri, S. K., and N. Singh. 2000. Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. Exp. Parasitol. 94:8-14.
74. Retsema, J., et al. 1987. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob. Agents Chemother. 31:1939-1947.
75. Roepe, P. D. 2009. Molecular and physiologic basis of quinoline drug resistance in Plasmodium falciparum malaria. Future Microbiol. 4:441-455.
76. Rogers, W. O., et al. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8:10.
77. Rottmann, M., et al. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175-1180.
78. Saliba, K. J., P. I. Folb, and P. J. Smith. 1998. Role for the Plasmodium falciparum digestive vacuole in chloroquine resistance. Biochem. Pharmacol. 56:313-320.
79. Sanchez, C. P., S. Wunsch, and M. Lanzer. 1997. Identification of a chloroquine importer in Plasmodium falciparum: differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. J. Biol. Chem. 272:2652-2658.
80. Seral, C., et al. 2003. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother. 47:1047-1051.
81. Sidhu, A. B., et al. 2007. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282:2494-2504.
82. Sidhu, A. B., D. Verdier-Pinard, and D. A. Fidock. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-213.
83. Singh, N., and S. K. Puri. 2000. Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 77:185-193.
84. Stopher, D. A., A. P. Beresford, P. V. Macrae, and M. J. Humphrey. 1988. The metabolism and pharmacokinetics of amlodipine in humans and animals. J. Cardiovasc. Pharmacol. 12(Suppl. 7):S55-S59.
85. Sullivan, D. J., Jr., I. Y. Gluzman, D. G. Russell, and D. E. Goldberg. 1996. On the molecular mechanism of chloroquine's antimalarial action. Proc. Natl. Acad. Sci. U. S. A. 93:11865-11870.
86. Thriemer, K., et al. 2010. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J. Infect. Dis. 202:392-398.
87. Uhlemann, A.-C., T. Staalsoe, M. Klinkert, and L. Hviid. 2000. Analysis of Plasmodium faciparum-infected red blood cells. MACS & more 4:7-8.
88. Waller, K. L., et al. 2003. Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J. Biol. Chem. 278:33593-33601.
89. Wells, T. N., P. L. Alonso, and W. E. Gutteridge. 2009. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8:879-891.
90. White, N. J. 2008. Qinghaosu (artemisinin): the price of success. Science 320:330-334. (Pubitemid 351555649)
91. Willet, G. P., W. K. Milhous, L. Gerena, and A. M. Oduola. 1991. Mixed population dynamics in human malaria parasite cultures. Trans. R. Soc. Trop. Med. Hyg. 85:33-34.
92. Wongsrichanalai, C., and S. R. Meshnick. 2008. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 14:716-719.
93. Wongsrichanalai, C., A. L. Pickard, W. H. Wernsdorfer, and S. R. Meshnick. 2002. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2:209-218.
94. Yeo, A. E., and K. H. Rieckmann. 1995. Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int. J. Parasitol. 25:531-532.
95. Zhang, X. P., K. E. Loke, S. Mital, S. Chahwala, and T. H. Hintze. 2002. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. 39:208-214.